InnoCare Pharma: Orelabrutinib supports growth, with a target of completing 2 BD deals by end-2026

Overview

This report is Goldman Sachs' conference takeaways following InnoCare Pharma's China Healthcare Corporate Day 2026. The key conclusion is that the company's BTK product Orelabrutinib continues to maintain a strong demand base despite policy disruptions, with approximately 30% sales growth guidance for 2026 unchanged; meanwhile, progress in the autoimmune pipeline and global BD partnerships represents a near- to medium-term catalyst.

Core views

First, the BTK business remains a stable growth pillar, with MZL accounting for approximately more than 40% of sales and 1L CLL/SLL accounting for over 50%; growth is continuing to accelerate from a larger base following NRDL inclusion. Second, expansion of the autoimmune pipeline enhances long-term optionality, with projects including ICP332, ICP488, oral IL-17, and VAV1 molecular glue offering multiple data readouts and filing milestones. Third, the company plans to complete approximately 2 BD deals by end-2026, with BCL2i becoming a priority asset due to its differentiated efficacy and safety profile.

Analysis framework

Goldman Sachs primarily assesses the investment attractiveness of InnoCare Pharma's H-shares and A-shares based on management communications, product sales momentum, clinical pipeline progress, BD discussion progress, and a risk-adjusted DCF valuation framework.

Methodology notes

• Valuation methodsRisk-adjusted DCF

  Risk-adjusted DCF valuation

  Goldman Sachs applies a risk-adjusted DCF valuation to InnoCare Pharma's H-shares, assuming a 12% discount rate and a 3% perpetual growth rate, to derive a 12-month target price of HK$20.54.

• relative_market_adjustmentA/H premium adjustment

  A/H premium adjustment

  Based on the one-year historical average A/H premium of 82%, the report derives an A-share 12-month target price of Rmb34.29 from the H-share target price.

• factor_profileGS Factor Profile

  Goldman Sachs factor profile

  The Goldman Sachs factor profile compares the stock with the market and industry peers across growth, financial returns, valuation multiples, and composite indicators.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• 09969.HK

  Core covered security; InnoCare Pharma H-shares.

  Strengths

  Orelabrutinib growth guidance remains intact, autoimmune pipeline catalysts are numerous, the BD deal target is clear, and Goldman Sachs assigns substantial implied upside.

  Weaknesses

  The long-term commercialization track record still requires further validation, and product sales may be affected by policy and pricing pressure.

  Comparison

  The report also covers A-share 688428.SS and derives the A-share target price through the A/H premium.

  Risks

  R&D failure, pricing uncertainty, potential entry of generic ibrutinib in China in 2027E, and slower-than-expected globalization progress.

• 688428.SS

  A-share proxy for the same company.

  Strengths

  Benefits from the same product portfolio and pipeline progress; Goldman Sachs also assigns it a Buy rating.

  Weaknesses

  The A-share target price depends on the A/H premium assumption and has relatively high valuation sensitivity.

  Comparison

  The H-share target price is HK$20.54, corresponding to an A-share target price of Rmb34.29; the A-share implied upside is 35.5%, below the H-share upside of 89.3%.

  Risks

  Changes in the A/H premium, shifts in market risk appetite, and execution risks.

Key data

• 09969.HK 12-month target priceHK$20.54Based on a risk-adjusted DCF, with a 12% discount rate and 3% perpetual growth rate.
• 09969.HK current priceHK$10.85Price disclosed in the report table.
• 09969.HK implied upside89.3%Derived from the target price and current price.
• 688428.SS 12-month target priceRmb34.29Derived based on the 82% historical average A/H premium.
• 688428.SS current priceRmb25.30Price disclosed in the report table.
• 688428.SS implied upside35.5%Derived from the target price and current price.
• Orelabrutinib 2026 sales growth guidanceApproximately 30%Management maintained its full-year guidance pending further clarity on policy impacts.
• MZL sales mixApproximately above 40%The report states that MZL continues to see new patient inflows.
• 1L CLL/SLL sales mixOver 50%Growth is accelerating from a larger base following NRDL inclusion.
• 2026 BD deal targetApproximately 2 dealsThe company aims to complete approximately 2 business development deals by end-2026, with BCL2i as a priority asset.

Impact & implications

If Orelabrutinib's sales resilience and autoimmune pipeline data are delivered, the company's fundamentals will gain greater visibility; if BCL2i, ICP332, or platform technologies secure global partnerships, this could improve market recognition of the external value of its R&D assets. The maintained Buy rating and substantial target-price upside indicate Goldman Sachs' positive view of its risk-reward profile.

Risks

• Key clinical assets carry R&D risk.
• The company lacks a longer-term, well-validated commercialization track record.
• Drug pricing remains uncertain.
• Generic ibrutinib may enter the Chinese market in 2027E, creating competitive pressure.
• Global expansion may progress more slowly than expected.
• Tightening anti-corruption policies may continue to affect physician interactions and conference participation, thereby affecting sales visibility.

What to watch

• Phase 3 topline data for ICP332 in atopic dermatitis, expected in July-August 2026.
• ICP332's targeted NDA submission in the first half of 2027.
• Phase 2 data for ICP332 in vitiligo and psoriasis, as well as Phase 1 data in CSU.
• Efficacy improvement with longer follow-up in ICP488's Phase 3 psoriasis study and its differentiated positioning in lupus and Sjögren's syndrome.
• Completion of the oral IL-17 Phase 1 trial by end-2026 and its potential weekly-dosing advantage.
• Progress in global partnership discussions for BCL2i and achievement of the approximately 2 BD deal target.
• The US$25mn milestone payment related to the initiation of the Phase 3 MS trial.